A method for the treatment of chlamydial conjunctivitis

 

(57) Abstract:

The invention relates to medicine, namely to ophthalmology, and is intended for treatment of chlamydial conjunctivitis. It is proposed to use a solution of ciprofloxacin at a dose of 1.0 ml, which is injected under the conjunctiva of the lower arch with its simultaneous introduction of the intravenous drip in 99 ml 2 times a day for 7-10 days. The method allows to increase the efficiency and reduce the time of treatment of chlamydial conjunctivitis.

The invention relates to medicine, namely to ophthalmology, and is intended for treatment of chlamydial conjunctivitis.

There is a method of treatment of chlamydial conjunctivitis antibiotic tetracycline (tetracycline and its semisynthetic derivatives - doxycycline, oxytetracycline, and others): local 1% tetracycline eye ointment 5-6 applications per day for 3-4 weeks and systematically inside of 0.5 g 2 times a day for a period of 10 days. However, often with long-term use of these drugs develops resistance often observed toxic-allergic reactions and other side effects. (Vachova E. C., abstract K. M. N., M., 1994, S. 3).

The closest in technical essence is a str is ciprofloxacina (ciprolet, cipromed) in the form of eye drops 4-6 times a day for 3 weeks in combination with systemic use: 1 tablet (250 mg) twice a day course of 10-14 days (Latypov, E. A., Malhanov Century B., Actual problems of ophthalmology, collection of scientific papers. Ufa, 1999, S. 234-238).

However, ciprofloxacin is in the form of eye drops (solution) is not intended for intraocular injection. (Information on medicines to health professionals, M, S. 271).

The aim of the invention is to increase the efficiency and reduce the time of treatment of chlamydial conjunctivitis.

This goal is achieved through the use of a solution of ciprofloxacin for intravenous injection, which is injected under the conjunctiva of the lower arch in the amount of 1.0 ml 2 times a day with its simultaneous introduction of the intravenous drip in 99 ml (198 mg) every 12 hours by course of 7-10 days.

The solution ciprofloxacin for injection is usually used to treat infections of bones and joints, bronchitis, pneumonia caused by susceptible microorganisms, bacterial infections, urinary tract infections, including urogenital chlamydial infection. (Information on medicines to health professionals, M, 19 the 0.25% solution dikaina under the conjunctiva of the lower arch on procaine cushion introduce a solution of ciprofloxacin in the amount of 1.0 ml (2 mg), and the other 99 ml (198 mg) intravenously. This procedure is repeated 2 times a day for 7-10 days.

Experimental studies conducted in 6 eyes of 3 rabbits revealed no toxic or irritant solution ciprofloxacin in polyconjugated the introduction of this drug in the amount of 1.0 ml 2 times a day during the week.

Under the proposed method were treated 7 patients (12 eyes) aged from 25 to 58 years. All patients received a positive therapeutic effect, while the average duration of treatment was 9,21,2 days. Recurrence was not observed.

In the control group, the integrated use of ciprofloxacin locally in the conjunctival cavity 4-6 instillations per day and inside at 250 mg twice daily for 10 days in 42 of the 47 patients (89%) resulted in clinical recovery average treatment time of 13.8 0.51 days. 5 patients out of 42 (11.8 per cent) after recovery had another relapse HC in 2-3 months, would necessitate re-treatment.

Example 1. Great Hours, 58 years old, was admitted with a diagnosis of Chronic chlamydial conjunctivitis in both eyes, infiltrative form. Complication: Purulent canaliculi left eye. Ill 8 . Admission: diffuse infiltration, redness of the conjunctiva of the eyelids, the lower vaults of the hull, from the conjunctival cavity Muco-purulent discharge. Left infiltration, redness of the lacrimal canals from the lachrymal points purulent discharge. Clinical diagnosis is confirmed by laboratory MFA the presence of conjunctival scraping antigen of chlamydia.

The solution ciprofloxacin introduced under the conjunctiva of the lower arch in a volume of 1.0 ml procaine cushion 2 times a day and simultaneously intravenously to 99 ml every 12 hours for 7 days. Improvement is noted after 3 days, decreased hyperemia, infiltration of the conjunctiva of the eyelids and the lower arch, purulent discharge from the cavity of the eye. On the 5th day significantly resorbed infiltration of the lacrimal canals disappeared purulent discharge from the lacrimal ducts on the left.

Big discharged from the hospital on day 8 with clinical recovery.

Example 2. B-Aya D., 48 years old, was admitted with a diagnosis of Chlamydial conjunctivitis, follicular form, chronic right eye. Concomitant Urogenital chlamydiosis. Chronic gastritis, cholecystitis. Otitis media on the right. Outpatient treatment (sulfacetamide, sofradex, pyrogenes, tetracycline ointment) on the occasion of the upper eyelid, hyperemia and edema of the conjunctiva of the eyeball, infiltration of the conjunctiva of the eyelids, in the lower vault of a large number of large, loose, sometimes merging follicles. The limb is extended, in the conjunctival cavity empyema.

After treatment with a solution of ciprofloxacin on the above method, eyes calm, residual infiltration of the conjunctiva of the eyelids, the follicles significantly apostiles and settled. Disappeared purulent discharge. On the 10th day of the big discharged from the hospital to outpatient aftercare.

Thus, the proposed method provides a high therapeutic effect and reduces the treatment time average of 4.6 days.

The drug is effective for the treatment of patients with various forms (papillary, infiltrative, follicular) chlamydial conjunctivitis and is particularly indicated in patients in severe and protracted cases of chlamydial conjunctivitis with concomitant urogenital infection, and in the presence of chronic diseases of the gastrointestinal tract, which is contraindicated antibiotics inside, and can be used in the treatment of other bacterial infections of the eyes.

The method of treatment stuff is in the quality of drug use a solution of ciprofloxacin at a dose of 1.0 ml, which is injected under the conjunctiva of the lower arch with the simultaneous introduction of the intravenous drip in 99 ml 2 times a day for 7-10 days.

 

Same patents:
The invention relates to medicine, namely to ophthalmology, and can be used for treatment of degenerative diseases of the cornea
The invention relates to medicine, namely to ophthalmology, and can be used for the treatment of recurrent secondary cataracts occurred on the background of a slow inflammatory process of various etiology

The invention relates to medicine, namely to ophthalmology, and can be used for the treatment of neovascularity
The invention relates to medicine, in particular to ophthalmology, and for the health of the retina and optic nerve in various pathologies of the eye

The invention relates to medicine, namely to ophthalmology, and can be used in the treatment of penetrating and non-penetrating injuries of the cornea

The invention relates to medicine, in particular to ophthalmology, and can be used for the treatment of diseases and injuries of the anterior surface of the eye

The invention relates to purified and dedicated not naturally occurring RNA ligands to vascular endothelial growth factor (VEGF) (indicated oligonucleotide sequence)
The invention relates to medicine, namely to ophthalmology, and can be used for the manufacture intracorneal lenses and implants, keratoprosthesis and artificial irises

The invention relates to medicine, in particular to the pharmaceutical industry

The invention relates to medicine and can be used in the treatment of tuberculosis

The invention relates to medicine, in particular to urology and andrology
The invention relates to medicine, specifically to a pharmaceutical composition having antimicrobial activity comprising as active principle an effective amount sulfalena and targeted supplements, which are used potato starch and/or corn, oxypropylation, magnesium stearate and/or calcium

The invention relates to new derivatives benzoylpyridine General formula (I), where R1means alkyl with 1-8 carbon atoms, a represents a group represented by the formula of the invention, means (-CH2-)aor (-CO-)band means an integer of 0 to 8, preferably 1, 2, 3 or 4, b means of 0,1 or 2, preferably 1, R2means unsubstituted or substituted alkyl with 1-8 carbon atoms, unsubstituted phenyl, NR3R4or preferably the five-membered heterocycle represented in the claims, in which U, V, W, X and Z can mean CH, NH, O or S, R3and R4denote alkyl with 1-8 carbon atoms

The invention relates to 4-(allumination)-2,4-dihydropyrazol-3-Onam General formula I, where R1denotes benzyl, alkoxybenzyl with 1-3 C-atoms in the alkyl part, unsubstituted or substituted once to three - fold amino, acyl, halogen, nitro, CN, AO, carboxyla, carbamoyl, N-allylcarbamate, N, N-dialkylammonium (with 1-6 C-atoms in the alkyl part), A-CO-NH-, AND-O-CO-NH-, AND-O-CO -, NA-, SO2NR4R5(R4and R5can denote H or alkyl with 1-6 C-atoms or NR4R5represents 5 - or 6-membered ring, optionally with other heteroatoms, like N, or O, which may be substituted),-CO-NH-SO2-, A-CO-NA-SO2- (AND-SO2-)2N-, tetrazolium phenyl; or pyridyl; R2denotes alkyl with 1-5 C-atoms, ethoxycarbonylmethyl, hydroxycarbonylmethyl; R3denotes unbranched or branched alkyl with 1-5 C-atoms, unbranched or branched alkoxy with 1-5 C-atoms or CF3And denotes unbranched or branched alkyl with 1-6 C-atoms or CF3and their salts

The invention relates to new derivatives of 4-(1-piperazinil)benzoic acid of formula I in which Ar represents a mono-, di - or tricyclic aryl having from 6 to 14 carbon atoms, while Ar may have from 1 to 3 substituents selected from the group comprising (C1-C8)alkyl, (C1-C8)alkoxy, halogen, trifluoromethyl; R1selected from the group comprising a hydrogen atom, cycloalkyl containing from 3 to 8 carbon atoms, (C6-C14)aryl, heteroaryl(C1-C6)alkyl, and heteroaryl selected from the group comprising furyl; R2and R3is hydrogen, a solvate and a pharmaceutically acceptable salt

The invention relates to medicine and can be used in dermatology for the treatment of chronic infections of the urogenital tract, namely disease Reiter

The invention relates to nitrogen-containing compounds that may constitute the active ingredient of the pharmaceutical composition active as an antagonist neirokinina, and more particularly to a derivative of arylpyrimidines and pharmaceutical compositions containing these compounds

The invention relates to arylalkylamines formula I, where In - unsubstituted pyridyl, pyrazinyl, isoxazolyl or thienyl; Q - CH2; X - CH2or S; R1and R2each - H; and R3- OR5; R4OA; R5- Or cycloalkyl with 4-6 C atoms; And the alkyl with 1-6 C-atoms, and their physiologically acceptable salts

FIELD: organic chemistry, heterocyclic compounds, medicine, pharmacy.

SUBSTANCE: invention relates to derivatives of heteroarylalkylpiperazine of the general formula (I):

wherein m = 1, 2 or 3; q means NH or oxygen atom (O); R1, R2, R3, R4 and R5 are taken independently among the group including hydrogen atom, (C1-C15)-alkyl, OR20 wherein R20 represents hydrogen atom; R6, R7 and R8 represent hydrogen atom; R9, R10, R11, R12, R13, R14, R15 and R16 are taken independently among the group including hydrogen atom, (C1-C4)-alkyl; or R9 and R10 in common with carbon atom to which they are joined form carbonyl group; R17 means heteroaryl that is taken among the group including indolyl, benzoxazolyl, benzothiazolyl, quinolinyl, isoquinolinyl, pyridyl, benzopyrazinyl substituted optionally with 1-2 substitutes taken among the group including hydrogen atom, CF3 group, (C1-C8)-alkyl, phenyl, CON(R20)2. Compounds elicit property as a partial inhibitor of oxidation of fatty acids and can be used in therapy for protection of skeletal muscles against results of muscular or systemic diseases. Also, invention describes a pharmaceutical composition based on the claimed compounds.

EFFECT: valuable medicinal properties of compounds.

39 cl, 3 tbl, 25 ex

Up!